Ivermectin effect on microfilariae of Onchocerca volvulus after a single oral dose in humans.
Ivermectin is a broad spectrum anti-helminthic agent which is currently being tested for use in human onchocerciasis. Its activity is believed to result from its effect on GABA-mediated neurotransmission. We examined the effects of ivermectin on motility of microfilariae of O. volvulus following administration to humans. When ivermectin was given in dosages of 100, 150 and 200 mcg/kg on day 1 there was a clear reduction in motility of microfilariae obtained on day 3 when compared to microfilariae from the placebo group. The mean motility scores in microfilariae from ivermectin recipients were 3.1, 2.3, and 2.2 at 0, 12, and 24 hours of incubation compared to 3.3, 2.9, and 2.5, respectively, in microfilariae from placebo recipients (p less than 0.003, p less than 0.005, and p less than 0.012, respectively). Examination of the effect according to dose suggested a dose-response relationship. Microfilariae in the anterior chamber of the eye 2 days after a single oral dose of ivermectin showed abnormal and reduced winding and coiling. Microfilariae in 50% of ivermectin recipients showed abnormal motility compared to no such effects in subjects examined concurrently who received oral DEC, DEC lotion or placebo. These observations indicate that ivermectin has an effect on motility of microfilariae of O. volvulus following administration to humans.
D000818:Animals; D004305:Dose-Response Relationship, Drug; D006801:Humans; D007559:Ivermectin / Q000494:pharmacology* / Q000627:therapeutic use; D008842:Microfilariae / Q000187:drug effects / Q000502:physiology; D009068:Movement / Q000187:drug effects; D009854:Onchocerca / Q000187:drug effects* / Q000502:physiology; D009855:Onchocerciasis / Q000188:drug therapy*
D007559:Ivermectin